Background: There are many contradictions about pregnancy and fetal/neonatal outcomes
after topical use of timolol alone or timolol in combination with other antiglaucoma medications.
Methods: Seventy-five pregnant women exposed to antiglaucoma medications were followed
prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol
as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women.
Results: Topical use of timolol alone or timolol in combination with other antiglaucoma medications
does not influence pregnancy or fetal/neonatal outcomes.
Conclusion: Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary,
multidrug therapy should not to be excluded.